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Commenting on “the record number of antidepressants
prescribed last year,” Helen Stokes-Lampard, chair of the Royal
College of General Practitioners, said that “research has shown
[antidepressants] can be very effective when used
appropriately.”1 This opinion about whether the number of
prescriptions is appropriate is one sided.
Firstly, evidence shows that only one in nine people benefit
from antidepressants: the remaining eight are unnecessarily put
at risk of adverse drug effects.2
Secondly, the effect size for antidepressants is modest,
plateauing at around 0.30 compared with placebo, and is based
on scales of questionable clinical relevance.2 Only one of the
17 items of the Hamilton Depression Rating Scale deal with
wellbeing, and the Montgomery-Åsberg Depression Rating
Scale has no such items.3
Thirdly, mood perturbations commonly reflect real life
circumstances. Many depressive presentations respond to
judicious “watchful waiting.” Most cases of depression, even
major or persisting, are successfully treated with psychosocial
interventions, which are preferred by patients, are beneficial for
self esteem and social functioning, and don’t have adverse
effects.3
Fourthly, the serious adverse effects of
antidepressants—including suicide attempts, cardiovascular
events, and severe withdrawal reaction after discontinuation of
long term pharmacotherapy—cannot be overlooked.4
Finally, treating resistant depression remains a challenge. Studies
sponsored by the drug industry have overestimated benefits and
underestimated harms.5-8 Writing a prescription should be
cautiously undertaken only after ruling out substance use,
ensuring better care for physical health problems, and
eliminating barriers to implementation of lifestyle enhancements.
In 2012 Allen Frances, chair of the task force that produced
DSM-IV, was a lone voice when he warned that DSM-5 “will
medicalise normality and result in a glut of unnecessary and
harmful drug prescription.”9 Unfortunately, he seems to have
been proven correct.
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